# Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

> **NCT01423084** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 344 (actual)

## Conditions studied

- Meningococcal Disease
- Meningococcal Meningitis

## Interventions

- **BIOLOGICAL:** Serogroup B meningococcal vaccine

## Key facts

- **NCT ID:** NCT01423084
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2015-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01423084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01423084, "Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01423084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*